 Vaxart Inc. NASDAQ:VXRT shares were trading higher Friday after the company plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the omicron SARS-CoV-2 variant in two studies expected to begin next month. The stock has climbed back above a key level that was holding as support for a time. 